Difference between revisions of "Increasing Private Funding (Venture Capital) for Biotech Research and Start-up financing"
| Line 3: | Line 3: | ||
==Enablers:== | ==Enablers:== | ||
• High ROE in Biotech investments | • High ROE in Biotech investments<br> | ||
• Attractive Profit margins for biotech drugs | • Attractive Profit margins for biotech drugs<br> | ||
• Controllable investment risk grace to clear and stable legal framework and transparent as well as stable approval rules. | • Controllable investment risk grace to clear and stable legal framework and transparent as well as stable approval rules. <br> | ||
• Reduction of R&D costs thanks to shift of research activities to emerging markets | • Reduction of R&D costs thanks to shift of research activities to emerging markets<br> | ||
• Reduction of R&D costs thanks to vast (and steadily increasing) amount of fundamental research available | • Reduction of R&D costs thanks to vast (and steadily increasing) amount of fundamental research available | ||
<br> | <br> | ||
==Inhibitors:== | ==Inhibitors:== | ||
• Insecurity regarding the development of legal frameworks | • Insecurity regarding the development of legal frameworks<br> | ||
• Drug approval authorities getting more and more strict | • Drug approval authorities getting more and more strict<br> | ||
• Time periods needed for drug development getting longer | • Time periods needed for drug development getting longer<br> | ||
• Other attractive investment topics | • Other attractive investment topics<br> | ||
==Paradigms:== | ==Paradigms:== | ||
• Is biotech still a hot topic for venture capital investors? | • Is biotech still a hot topic for venture capital investors?<br> | ||
==Experts== | ==Experts== | ||
| Line 23: | Line 23: | ||
==Timing== | ==Timing== | ||
• Tysabri: Suspension of sale per 28.2.05, eventually withdrawn form the market | • Tysabri: Suspension of sale per 28.2.05, eventually withdrawn form the market<br> | ||
• Vioxx: Withdrawn from the market per 30. 9.2004 | • Vioxx: Withdrawn from the market per 30. 9.2004<br> | ||
• Veto of US President Bush against Stem Cell Research Bill: May 20, 2005 | • Veto of US President Bush against Stem Cell Research Bill: May 20, 2005<br> | ||
==Web Resources== | ==Web Resources== | ||
See our financial research: Link to our financial research | See our financial research: Link to our financial research | ||
Revision as of 13:14, 2 December 2005
Description:
The US Biotech Industry is largely built on Private Venture Capital. Willingness of Private investors to continue sponsoring biotech depends on perspectives of the biotech industry with regards to growth, profitability and scalability. As long as Biotechnology is perceived as a growth industry, venture capital will be available.
Enablers:
• High ROE in Biotech investments
• Attractive Profit margins for biotech drugs
• Controllable investment risk grace to clear and stable legal framework and transparent as well as stable approval rules.
• Reduction of R&D costs thanks to shift of research activities to emerging markets
• Reduction of R&D costs thanks to vast (and steadily increasing) amount of fundamental research available
Inhibitors:
• Insecurity regarding the development of legal frameworks
• Drug approval authorities getting more and more strict
• Time periods needed for drug development getting longer
• Other attractive investment topics
Paradigms:
• Is biotech still a hot topic for venture capital investors?
Experts
See our Financial Research: Link
Timing
• Tysabri: Suspension of sale per 28.2.05, eventually withdrawn form the market
• Vioxx: Withdrawn from the market per 30. 9.2004
• Veto of US President Bush against Stem Cell Research Bill: May 20, 2005
Web Resources
See our financial research: Link to our financial research